Carbidopa 25 MG Levodopa 100 MG Oral Tablet

INDICATIONS AND USAGE Carbidopa and levodopa tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. Carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa.

Mylan Pharmaceuticals Inc.

FDA Reported Adverse Reactions
`[1] fatigue` `[2] drug ineffective` `[3] nausea` `[4] dyspnoea` `[5] diarrhoea` `[6] pain` `[7] headache` `[8] off label use` `[9] dizziness` `[10] vomiting`

5 years ago

ROUND YELLOW M CL2

HOW SUPPLIED

CARBIDOPA AND LEVODOPA Tablets, USP are available containing 10 mg or 25 mg of carbidopa, USP and 100 mg or 250 mg of levodopa, USP. The 10 mg/100 mg tablets are blue, round, scored tablets debossed with M above the score and CL1 below the score on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-0078-01 bottles of 100 tablets The 25 mg/100 mg tablets are yellow, round, scored tablets debossed with M above the score and CL2 below the score on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-0085-01 bottles of 100 tablets The 25 mg/250 mg tablets are blue, round, scored tablets debossed with M above the score and CL3 below the score on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-1133-01 bottles of 100 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: ALPHAPHARM PTY LTD 15 Garnet Street Carole Park QLD 4300 Australia Revised: 10/2022 ALP:CDLDT:R2 3478/1

More pills like ROUND M CL2

Related Pills

Carbidopa and Levodopa Carbidopa 25 MG Levodopa 100 MG Oral Tablet

Mylan Pharmaceuticals Inc.

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site